Therapeutic effect of dexmedetomidine on myocardial ischemia reperfusion injury in type 2 diabetic rat model under P13K/Akt pathway

Abstract

This research aims to study the therapeutic effect of dexmedetomidine on type 2 diabetic rats reperfusion injury model. A rat model of type 2 diabetes was induced by high-fat and high-sugar feed, and a reperfusion rat model was obtained by ligating the left anterior descending branch and reperfusion. The diabetic rat model sham operation group was used as the control group (DM-S), the rats were divided into diabetic reperfusion group (DM-IR) and dexmedetomidine treatment group (DM-D), dexmedetomidine combined with DM-DW (DM-DW), and Wortmannin treatment group (DM-W). In this study, the MB isoenzyme of creatine kinase (CK-MB) concentration was determined by ELISA competition method, superoxide dismutase (SOD) activity in rat plasma was detected by superoxide dismutase WST-1, and the content of malonaldehyde (MDA) in rat plasma was determined by thiobarbituric acid method. Besides, Western Blot was used to detect the expression changes of Akt, P-Akt, GSK-3β, and P-GSK-3β in rat myocardial tissue. The results showed that the content of CK-MB and SOD in DM-D group was significantly higher than that in DM-IR group (P < 0.05), and the content of MAD was significantly lower than that in DM-IR group (P < 0.05). The content of CK-MB and SOD in DM-DW group and DM-W group were significantly higher than that in DM-D group (P < 0.05), and the content of MDA was significantly lower than that in DM-D group (P < 0.05). However, expression of p-Akt and p-GSK-3β protein in DM-D group was significantly higher than that in DM-DW group and DM-W group (p < 0.05). Accordingly, dexmedetomidine can play a role in treating myocardial ischemia-reperfusion injury in type 2 diabetes by regulating the expression of related genes in the P13K/Akt signaling pathway.